ARIAD Pharmaceuticals

ARIAD is a global oncology company focused on the discovery, development and commercialization of medicines for the cancer patients.

Launch date

1991

Employees

Market cap

Enterprise valuation

CAD7.1b (Public information from Jan 2017)

Cambridge Massachusetts (HQ)

Revenues, earnings & profits over time

EUR	2015
R&D budget	152m

Source: Dealroom estimates

Date	Investors	Amount	Round
-	Medicxi Ventures	N/A	-
Mar 1992	Avalon Ventures Forward Ventures BB Biotech Wellington Access Ventures	$46.0m	Early VC
Sep 1994	N/A	N/A	IPO
Nov 2001	N/A	$8.0m	Post IPO Equity
Nov 2002	N/A	$6.1m	Post IPO Equity
May 2003	Merlin Biomed	$10.0m	Post IPO Equity
Oct 2003	N/A	$41.0m	Post IPO Equity
Dec 2003	N/A	$9.4m	Post IPO Equity
Oct 2006	Credit Suisse	$14.0m	Post IPO Equity
Jan 2017	Takeda	$5.2b Valuation: $5.2b	Acquisition
Total Funding		CAD62.7m

Tech stackLearn more about the technologies and tools that this company uses.

ACQUISITION by Concentra Biosciences Dec 2023

Financials